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STAT                                      Signal transducer and activator of transcription 
TGF                                        Tumor growth factor 
TGF-α                                     Transforming Growth Factor-alpha  
TGF-β                                     Transforming Growth Factor-beta  
TGFβR2                                  Transforming Growth Factor-β II Receptor 
TKI                                         Tyrosine Kinase Inhibitor 
TLC                                         Thin layer chromatography 
TLRs                                        Toll like receptors 
TNF                                         Tumor necrosis factor 
UV-Vis                                    Ultraviolet-Visible   
VEGF                                      Vascular Endothelial Growth Factor  
VEGFR 1 and 2                      Vascular Endothelial Growth Factor Receptors 1 and 2 
VCAM-1                                 Vascular cell adhesion molecule-1 
  
XVIII 
 
KAJIAN ANTI-TUMOR HERBA-HERBA ASLI SUDAN YANG TERPILIH 
MELALUI LALUAN ANGIOGENESIS 
ABSTRAK 
Tujuan kajian ini adalah untuk mengkaji enam tumbuhan ubatan Sudan untuk aktiviti 
antikanser. Bahagian berbeza daripada tumbuhan-tumbuhan ini telah dipilih untuk 
menyediakan 32 ekstrak menggunakan kaedah pengekstrakan berturutan dengan 4 
jenis pelarut yang berbeza kekutuban. Antara keenam-enam tumbuhan ubatan Sudan 
yang telah diuji itu, N. glauca, T. apollinea, C. hartmannianum and T. nilotica telah 
didapati sangat aktif secara biologi dengan kesan-kesan “antiangiogenic” dan 
“antineoplastic” yang bererti. Aktiviti-aktiviti biologi tersebut didapati telah 
disebabkan oleh aktiviti antioksida berikutan kehadiran bahan-bahan fenolik dan 
flavonoid yang tinggi. Keputusan-keputusan kajian ini menunjukkan bahawa ekstrak 
etanol T. apollinea mempunyai kesan “antiangiogenic” yang tertinggi berbanding 
spesis tumbuhan lain dan ia juga merencatkan pertumbuhan kanser kolon “in 
vivo”secara bererti. Ekstrak tersebut didapati menghentikan “angiogenesis” dengan  
merencatkan penghijrahan sel, pembentukan saluran endothelial dan yang terpenting 
sekali, merencatkan pengungkapan “VEGF”. 
Sebatian-sebatian yang penting yang menyumbang kepada aktiviti ini adalah tiga 
“prenylated flavonoids” iaitu “(-)-pseudosemiglabrin (SSG)”, “(-)-semiglabrin (SG)” 
dan “isoglabratephrin (IGP)”. SSG telah didapati wujud dengan banyak dan adalah 
yang paling aktif sebagai “antiangiogenic” berbanding SG dan IGP. SSG 
merencatkan enzim “COX” dengan keutamaan tinggi terhadap enzim “COX-2”. Ia 
juga menyekat penghasilan “cytokines” IL-1 dan TNF-α tetapi ia tidak mempunyai 
kesan yang bererti terhadap pengungkapan nitric oksida (NO). IL-1 dan TNF-α 
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adalah perantara-perantara keradangan yang penting yang memainkan peranan yang 
amat genting dalam karsinogenesis. SSG telah menunjukkan aktiviti antitumor “in 
vivo” yang kuat terhadap model xenograft kanser kolon ektopik dan ortotopik dengan 
yang kedua menunjukkan perencatan pengungkapan MMP-9. Antara ketiga-tiga 
sebatian tersebut, hanya SSG yang menunjukkan aktiviti sitotoksik terutamanya 
terhadap titisan-titisan sel kanser kolon (HCT116), kanser payudara (MCF7), kanser 
prostat (PC3) dan leukemia (HL-60). Sebatian tersebut menyasarkan fungsi 
mitokondrion dengan mengganggu keutuhan matriks sel. Sebatian-sebatian yang 
telah diasingkan itu digunakan untuk memiawaikan ekstrak etanol T. apollinea 
menerusi kaedah HPLC. Kajian ini telah menunjukkan sebahagian besar aktiviti 
“antiangiogenic” dan antitumor ekstrak etanol T. apollinea disumbangkan oleh SSG. 
Kesimpulannya, keputusan ini menunjukkan bahawa ekstrak T. apollinea dan 
sebatian aktifnya iaitu SSG sebagai ejen-ejen antitumor yang berpotensi yang 
mengubah aktiviti mereka melalui lata “antiproliferative” dan “angiogenesis”. 
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ANTI-TUMOR STUDIES OF A SELECTION OF SUDANESE INDIGENOUS 
HERBS VIA THE ANGIOGENESIS PATHWAY  
 
ABSTRACT 
The aim of the present study is to investigate six Sudanese medicinal plants for 
anticancer activity.   Different parts of these plants were selected to prepare 32 
extracts using sequential extraction method with 4 solvents of different polarity.  
Amongst the six Sudanese medicinal plants tested, N. glauca, T. apollinea, C. 
hartmannianum and T. nilotica were found to be most biologically active with 
significant antiangiogenic and antineoplastic effects. Their biological activities 
observed were found to be attributed to their high antioxidant activity due to the 
presence of high amount of phenolic and flavonoid substances.  
The results of present study indicate that the ethanol extract of T. apollinea possess 
the highest antiangiogenic effect when compared to the other plant species and it 
significantly inhibited the growth of colon cancer in vivo. The extract was found to 
halt angiogenesis by inhibiting cell migration, endothelial tube formation and most 
importantly the inhibition of VEGF expression.   The key compounds that contribute 
to this activity are three prenylated flavonoids namely (-)-pseudosemiglabrin (SSG), 
(-)-semiglabrin (SG) and Isoglabratephrin (IGP). SSG was found to be the most 
abundant and the most active as antiangiogenic when compared to SG and IPG. SSG 
inhibits the COX enzymes with strong preference towards the COX-2 enzymes.  It 
also suppresses production of cytokines IL-1 and TNF-α but it  not significant effect 
towards nitric oxide (NO) expression, IL-1 and TNF-α are key inflammatory 
mediators that plays crucial role in carcinogenesis. SSG showed potent in vivo 
antitumor activity towards ectopic and orthotopic xenograft model of colon cancer 
with the latter indicating the inhibition MMP 9 expression. Amongst the three 
compounds only SSG showed cytotoxic activity particularly towards colon cancer 
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(HCT116), breast cancer (MCF7), prostate cancer (PC3) and leukemia (HL-60) cell 
lines. The compound targets the mitochondrial function by disrupting the integrity of 
its cellular matrix. The isolated compounds were used to standardize the ethanol 
extract of T. apollinea by HPLC method. The study indicated that the antiangiogenic 
and antitumor activity of T. apollinea ethanol extract is contributed mainly by SSG.  
All in all, the data shows that extract of T. apollinea and its active compound SSG, as 
potential antitumor agents that modulate their activity via the antiproliferative and 
angiogenesis cascade. 
1 
CHAPTER 1 
INTORDUCTION 
 
1.1 Cancer  
Cancer is a group of diseases which is characterized by aggressive cell 
growth and division that exceeds normal cells. They invade and destroy neighboring 
tissues, and often spread to other locations of the body (metastasis). These three 
properties of cancer differentiate neoplasic tissues from benign tumors which are 
self-regulated, limited growth potential with no ability to metastasize (Gatta et al., 
2013). Almost all cancers occur due to abnormality (mutation) in the genetic 
material of the transformed cells. The abnormalities are attributed to the effects of 
carcinogens, such as radiation, chemicals tobacco smoke or infectious agents 
(Mediana, 2008). Abnormality in genetic material may occur randomly due to error 
in DNA replication, or inherited, thereby originated in all cells from birth, which 
lead to genetic damage that, if not repaired, results in irreversible mutation. The 
altered cells grow till formation a colony, afterwards the mutated cells grow under 
the promotion of carcinogens or other factors via changing the environment in way 
that support the growth of mutated cells over normal cells (Mediana, 2008). The 
next stage is transformation’ of mutated cells to cancerous cells, it may takes 5-20 
years may require for the transition of benign carcinogenic phase to the fully 
developed malignant stage where  the  cancer  can  be  detected  clinically. The  last  
stage  called  progression, where  further  genetically  changes  take  place  leading  
to  increase  the  proliferation  and metastasis (Marshall, 1991). 
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1.1.2 Hallmark of Cancer  
Emerging evidence proposed six complementary and  distinctive hallmarks 
that enable the initiation, growth and metastasis of tumor, these characteristic 
features provide solid platform of understanding cancer biology (Douglas Hanahan 
& Weinberg, 2011). 
 
1.1.2.1 Sustaining Proliferative Signaling  
The main characteristic feature of cancer cells constitutes the ability of 
chronic proliferation, due to the loss of control over the production and release of 
growth-promoting signals that regulate the process of cell growth and cell division, 
thus cancer cells no longer depend on external signals, while these signals in normal 
cells are well controlled to enable homeostasis of cell. Moreover, tumor cells 
become antagonist to anti-growth signals or they cannot respond to normal signals 
that regulate or limit the cell division(Douglas Hanahan & Weinberg, 2011). 
 
1.1.2.2 Evading growth suppressors 
In addition to the characteristic feature of inducing and sustaining positively 
acting growth-stimulatory signals, cancer cells must also circumvent powerful 
programs that negatively regulate cell proliferation; many of these programs depend 
on the actions of tumor suppressor genes. Dozens of tumor suppressors that operate 
in various ways to limit cell growth and proliferation have been discovered through 
their characteristic inactivation in one or another form of animal or human cancer; 
many of these genes have been validated as bona ﬁde tumor suppressors through 
gain- or loss-of-function experiments in mice. The two prototypical tumor 
suppressors encode the RB (retinoblastoma-associated) and TP53 proteins; they 
operate as central control nodes within two key complementary cellular regulatory 
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circuits that govern the decisions of cells to proliferate or, alternatively, activate 
senescence and apoptotic programs.   
 
The RB protein integrates signals from diverse extracellular and intracellular sources 
and, in response, decides whether or not a cell should proceed through its growth-
and-division cycle (Burkhart & Sage, 2008; Sherr & McCormick, 2002). Both 
examples must reﬂect the operations of redundantly acting mechanisms that serve to 
constrain inappropriate replication of cells lacking these key proliferation 
suppressors. 
 
1.1.2.3 Evading apoptosis  
The major trait of cancer cells is increase cell populations not only by cell 
proliferation but also by the rate cell attrition. Apoptosis (cell programmed death) 
responsible for attrition, so apoptosis represent vital mechanism to eliminate 
damaged cells and avoid mutations that can lead to tumor formation. Cancer cells 
acquired resistance to apoptosis via different strategies. Mainly due to the loss of a 
proapototic regulator through p53 suppressor gene mutation (Harris, 1996).  
 
1.1.2.4 Enabling replicative immortality  
Almost all types of cancers are believed to originate from a single cell, which 
acquired capability of limitless replicative potentials. In order to become visible 
mass, the cells must divide almost unlimited times. Normal cells are unable to  grow 
and divide indefinitely, because they are limited in the number of times they can 
efficiently copy all the cell’s DNA, because telomeres i.e the caps of repetitive 
sequence of DNA at the end of each strand of DNA which are truncated during cell 
division. As the cell divides more and more its telomeres shorten leading the cell to 
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inter non-replicative state- a process termed senescence (Bodnar et al., 1998) . This 
mechanism limits cellular replicative potential. Malignant cells have routes to avoid 
cellular senescence to divide indefinitely and form tumors. This involve finding 
ways of repairing or lengthening the telomeres to protect them from being 
shortened, therefore facilitating indefinite replication(O'Sullivan & Karlseder, 2010).  
Telomerase is an enzyme which accumulates telomere sequences to the ends of 
chromosomes to avoid termination of replication; some normal cells express 
telomerase, such as embryonic stem cell, in which cells replicate indefinitely, but 
this not apply to adult cells. Many malignancies constitute mutations that lead to 
activation of telomerase, which results in replicative immortality (Hayflick, 1997). 
 
1.1.2.5 Sustained Angiogenesis 
Similar to normal tissues, tumor mass requires oxygen and nutrients. For a 
tumor to grow bigger than 2mm3 in size it must establishment blood supply in 
process by which the host’s vasculature is extended and neovasculature grows into 
tumor i.e called angiogenesis. There are no distinct changes by tumor themselves, 
this process transitory and carefully regulated by tumor mass and the host tissue. 
Tumors initiates pathological angiogenesis by unbalancing angiogenesis inducers 
and countervailing inhibitors (D. Hanahan & Folkman, 1996). Changing the balance 
could be due to change in gene transcription. Evidence shows elevated expression of 
VEGF and/or FGFs in tumor tissues compared to normal tissue, down regulation of  
endogenous inhibitors such as thrombospondin-1 orb-interferon may associated with 
over expression of growth factors (Singh et al., 1995). 
1.1.2.6 Invasion and metastasis  
Cancer cells acquired the capability to become motile, migrate from primary 
tumor and invade adjacent tissues, and thence spreading to other site of the body 
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(metastasis), where they may form new tumors (secondary tumors). Metastasis and 
secondary tumors caused 90% of cancer patients mortality (Sporn, 1996). Invasion 
and metastasis are allied and complicated process. Invasion promoted by changes in 
the expression of surface marker which allow the cells to adhere to the surrounding 
tissues. Cancer cells invade blood vessels and move through circulatory system to 
different site of the body. These processes not completely understood, but it’s 
known that several proteins which secreted to break down the tissue and allow 
invasion of cancer cells into blood vessels and eventually form new tumor at the site 
of settlement (a metastasis). These proteins include cell–cell adhesion molecules 
(CAMs), in addition to members of the immunoglobulin and calcium-dependent 
cadherin families both of which mediate cell-to-cell interactions, also integrins, 
which link cells to extracellular matrix substrates (Albelda, 1993).   
1.2 Angiogenesis 
Angiogenesis is the formation of new blood vessels from existing 
vasculature. Its biological process occurs in both pathological and health life. It’s 
well-regulated in physiological process such as embryogenic development, female 
reproductive tract in uterus and placenta during pregnancy, in addition to wound 
healing process, while in disease stage it is deregulated in many pathological 
conditions including tumor growth and metastasis, rheumatoid arthritis, psoriasis, 
diabetic and obesity (Adair & Montani, 2010; Peter Carmeliet, 2005). Tumor 
angiogenesis is crucial for cancer growth and metastasis, thus targeting angiogenesis 
is of great therapeutic value, recently this field studied extensively to utilize pro- and 
antiangiogenic agents. Angiogenesis play a fundamental role in tumor growth as the 
tumor unable to grow more than 1-2 mm2 without sufficient oxygen and nutrients, 
the newly formed blood vessels not only used for supplying nutrient and oxygen but 
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also can be utilized by tumor to metastasis to other locations (Ou et al., 1998). Thus 
targeting tumor angiogenesis became a cutting edge in cancer therapy, due to 
interdependence between cancer and angiogenesis and less side effect of inhibiting 
angiogenesis only under special circumstances such as pregnancy and not fully 
grown individuals. A huge effort has been assigned to screen or to develop 
antiangiogenic compounds to treat cancer and other angiogenic related diseases. 
 
1.2.1 The Vascular Endothelial Growth Factor (VEGF) 
VEGF is a signal protein that stimulate various steps in angiogenesis cascade 
such as cell proliferation, migration and cell survival of endothelial cells (Figg & 
Folkman, 2008). When VEGF over expressed it contribute to disease, for instance 
when solid tumors grow in size, the demand for oxygen increases causing release of 
oxygen free radical which in turn stimulate vascular endothelial growth factor 
(VEGF) that trigger tumor angiogenesis (Mukhopadhyay et al., 1995). It’s reported 
that VEGF level is upregulated in RNA and protein of many types of malignancy. 
The elevated level of VEGF in cancer patients is associated with low survival rate 
and poor prognosis (Paley et al., 1997). The biological effects of VEGF family are 
mediated by three tyrosine kinase receptors, VEGFR-1, VEGFR-2 and VEGFR-3 
(Wirzenius, 2007). VEGF-A is growth factor with specificity to endothelial cells 
that had been regarded as a heparin binding angiogenic growth factor (Wirzenius, 
2007), it  belongs to a gene family that includes placenta growth factor (PGF), 
VEGF-B, VEGF-C, VEGF-D and VEGF-E. The main difference between  these 
proteins  is  the type  of  receptors  they  bind to  and  activate;  PGF,  VEGF-B  can  
bind  with  VEGFR-1 and VEGF-C, VEGF-D binds with VEGF-3, and VEGF-A 
can bind with two  receptors: VEGFR-1 and VEGFR-2 (Shibuya, 2001). 
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VEGF play vital role in tumor angiogenesis, in turn tumor growth and 
metastasis, rendering it as good target for cancer therapy via deactivation of VEGF 
by neutralizing antibodies or by  introduction of dominant negative  VEGF  
receptors (K. J. Kim et al., 1993). 
 
1.2.2 Angiogenesis Process Cascade 
In the angiogenesis cascade, a number of biological processes occur. 
Figure1.2 depicts the steps of angiogenesis process. Angiogenesis initiated 
vasodilation of existing blood vessels to increase permeability to angiogenesis 
signals. Then, the pericytes that covers the blood vessels, detach followed by 
degradation of vascular membrane and extracellular matrix (figure 1.3 a) which 
allow for the activated endothelial cells  to  migrate  into  the  perivascular  space  
towards  chemotactic  angiogenic  stimuli (Napoleone Ferrara, 1999). The migrated 
endothelial cells proliferate, loosely following each other into the perivascular space 
and form migration columns. Then, the endothelial cells differentiate; cells‘  shape 
change  in a way  that  facilitates  the cell-cell adherence  which  then  forms  a  
lumen  (tube-like  structure).  Perivascular cells are attracted, and a vascular basal 
lamina is produced around the newly formed vessels. The details are still vastly 
obscure for the last stages when vascular sprouts fuse with other sprouts to form 
loops ((Bergers & Benjamin, 2003; Peter Carmeliet, 2005).  
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Figure 1.1: The angiogenesis process (physiological and pathological) cascade (Chung, Lee, & Ferrara, 
2010)  
 
1.2.3 Cancer is Angiogenesis Dependent 
Studies proved that there is interdendency between tumor growth and 
neovascularisation. The blood supply and number/size of vessels must be 
proportional to tumor size (J. Folkman, 1990). The hypothesis has been proved by 
many studies. This proof that angiogenesis inhibitors can effectively utilized to 
combat cancer. Several preclinical studies proved that solid tumors need new blood 
vessels to grow. In one study, the tumors which implanted in corneas, the tumors 
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start to grow only after the new blood vessels reach the implant. It’s noticed that 
introduction of angiogenic genes can transform dormant tumor into progressive and 
growing tumor. Moreover it’s evident that some specific angiogenesis inhibitors can 
suppress tumor growth by modulating vascular compartment (Goel et al., 2011).  
 
1.2.4 The Angiogenic Switch 
Mutation in somatic cell leads to transformation of normal cells to cancerous 
cell, the latter divide rapidly to form tiny tumor called in situ carcinoma. The 
estimated time needed to develop complete tumogenesis from benign carcinogenic 
and to be detected clinically is about five to twenty years (Judah Folkman, 1995; 
Mediana, 2008). At dormant stage cancer cells start to proliferate at the same time 
the rate of cell death continues and maintain the mass of the tumor at stable state 
(Ribatti, 2009). At this situation, there is a balance between two opposite signals; 
angiogenesis signals like VEGF expression (N Ferrara, 2002) and antiangiogenesis 
signals (e.g., Endostatin, Angiostatin) (H. Kim et al., 2000). Therefore, the 
formation of new blood vessels starts when  the  net balance  between  these  
divergent  signals  is  tipped  in  favor  of  angiogenesis  initiation (Judah Folkman, 
1995; Douglas Hanahan & Weinberg, 2011). Obviously, identification and 
impairing of factors and circumstances which enhance initiation of angiogenesis 
may keep the tumor in dormancy stage (Goel et al., 2011). Studies revealed that 
angiogenesis process can be initiated by different signal such as genetic mutation, 
metabolic stress (e.g hypoxia, hypoglycemia), mechanical  stress  (e.g.,  pressure  
generated  by  proliferating  cells, and immune/inflammatory  response 
(immune/inflammatory  cells  that  have  penetrate the tissue) (Douglas Hanahan & 
Weinberg, 2000). This environment facilitate synthesis and release of key 
angiogenic factor like VEGF (P. Carmeliet, 2005). 
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1.2.5 Hypoxia 
Hypoxia is a condition in which the body or a region of the body is deprived 
of adequate oxygen supply required for cellular functions. Cells experience hypoxia 
when it is located too far from blood supply. As the tumor grow bigger the cells in 
centre of the tumor become hypoxic (Peter Carmeliet, 2005). Recent report 
demonstrated that hypoxia inducible transcription factors (HIFs) that activated in 
hypoxic cells play fundamental role in angiogenesis cascade (Bos et al., 2001). 
Ligation of the HIFs with the DNA activates major angiogenic factors such as 
PDGF, VEGF and nitric oxide synthase (Ahmed & Bicknell, 2009). HIF-1 and HIF-
2 and the main principles of HIFs, HIF-1 expressed only in endothelial cells, the 
heart, small intestine, lungs and kidneys, whereas HIF-2 is expressed ubiquitously. 
HIF-1 is heterodimer containing two DNA binding protein receptors, HIF-1α and 
HIF-1β. HIF-1α expression is strongly organized by oxygen, whereas the HIF-1β is 
expressed constitutively (Stroka et al., 2001). In normal situation HIF-1α is swiftly 
degraded by enzymatic prolylhydroxylation. Nonetheless, in hypoxic stage the HIF-
1α becomes stable and its half life increases significantly. Thus, HIF-1α dimerizes 
with HIF-1β. The heterodimer is then transferred to the nucleus and activates the 
promoter region of specific genes (Adair & Montani, 2010). The activation of HIF-α 
involved in the in the expression of (VEGF), which is a major growth factor in the 
angiogenesis. HIF represent a good target for angiogenic and cancer therapy. This 
hypnosis proved by study in mice  implanted with  cells  infected with a polypeptide 
which  abolish the  binding  of HIF-1α  to  its  transcriptional  co-activators, which 
showed significant reduction of tumor growth (Ryan et al., 2000)  Some natural 
compounds such as Klugine, betulinic acid, taxol, isocephaeline and emetine 
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excelled their mechanism of action to inhibit hypoxia pathway (Assudani, Tyagi, & 
Vimalanathan, 2010). 
 
1.2.6 Angiogenesis Targets 
Tumor neovasculature is sophisticated multi-steps process. It could be 
inhibited by agents that interrupt the key steps of this process, such as (1) inhibition 
of growth factor signal production, inhibition of receptors production and /or inhibit 
the binding between signals and receptors, which modulate the activation of 
endothelial cells. (2)  inhibition of endothelial cells proliferation,  (3)  inhibition  of  
endothelial  cells migration,  (4)  inhibition  of  endothelial cells differentiation  to 
form a  three dimensional  tube-like structure and (5) induction of apoptosis in 
endothelial cells (Zhang & Bicknell, 2003).  
 
1.3 Inflammation & Cancer 
The functional relationship between cancer and inflammation is known since 
1863, when Virchow hypothesized that cancer could be a precursor of chronic 
inflammation. This obvious when some kind of irritants associated with tissue injury 
and ensuing inflammation, many factors directly or indirectly enhance cell 
proliferation (Fran Balkwill & Alberto Mantovani, 2001), recruit inflammatory cells, 
increase production of reactive oxygen species leading to oxidative DNA damage, 
and reduce DNA repair.  Subversion of cell death and/or repair programmes occurs 
in chronically inflamed tissues, thus resulting in DNA replication and proliferation 
of cells that have lost normal growth control. Normal inflammation is self-limiting, 
because the production of anti-inflammatory cytokines follows the pro-inflammatory 
cytokines closely. However, chronic inflammation seems to be due to persistence of 
the initiating factors or a failure of mechanisms required for resolving the 
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inflammatory response (Coussens & Werb, 2002). In prolonged tissue injury 
associated with wound healing, cells carry on proliferation while the tissue 
regenerates, the proliferating cells that sustain DNA damage and/or mutagenic 
assault continue to proliferate in microenvironments rich in inflammatory cells and 
growth factors that support their growth and up-regulate gene transcription factors 
such as NF-κB. In a sense, tumors act as wounds that couldn’t to heal (Dvorak, 
1986). The inflammation mediates host defense to pathogenic infection or irritants 
and regulates regeneration of afflicted tissue. It’s evident from epidemiologic studies 
that there is obvious connection between inflammation and initiation of 
tumorigenesis. It estimated that 15% of cancer incidence worldwide attributed to 
microbial infection, of 1.2 million per year  (Kuper, Adami, & Trichopoulos, 2000; 
Shacter & Weitzman, 2002). Continual infections within the host induce chronic 
inflammation. Leukocytes and other phagocytic cells degrade the DNA of 
proliferating cells, via their production of reactive oxygen and nitrogen species 
which combat infection. These species react to form peroxynitrite, a mutagenic 
agent (Maeda & Akaike, 1998). Thus, frequent tissue damage and regeneration of 
tissue, in environment rich of reactive nitrogen and oxygen species generated from 
inflammatory cells, interacts with DNA in proliferating epithelium resulting in 
permanent genomic alterations such as point mutations, deletions, or 
rearrangements. For instance, p53 mutations found frequently in individuals whom 
developed tumors due to choric inflammation such as inflammatory bowel disease 
(Yamanishi et al., 2002). Excess DNA damage by inflammatory cells is expression 
of macrophage migration inhibitory factor (MIF) from macrophages and T 
lymphocytes. MIF is a strong cytokine that up-regulates p53 function by suppressing 
its transcriptional activity (Hudson et al., 1999). Continual avoid of p53 regulatory 
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processes in the inflamed tissues can increase proliferation and prolong life span,   
also creating an environment with a poor response to DNA damage, leading to 
potential gene mutations. 
Chemokines are multifunctional mediators mainly it direct the migration of 
leukocytes to inflamed site; however, chemokine biology extends to all cell types, 
including most human cancer cells (Ehrlich, 2000). This notion was supported by 
the role of chemokines during induction of tumor into an experimental animals 
deficient to T or natural killer (NK) cells, it exhibited typical inflammatory infiltrate; 
which indicate that the neoplastic cells produce chemotactic factors or induce their 
expression in neibouring cells of the host (Brummer, Vinoda, & Stevens, 2006) . 
Some cancer cells regulate their chemokines to recruit inflammatory cells as well as 
using these factors to enhance tumor growth and progression. For example in 
melanoma chemokines and their receptors (GROα/CXCL1, 
GROβ/CXCL2,GROγ/CXCL3 and IL-8/CXCL8) shown to have autocrine control 
over tumor cell proliferation (Richmond & Thomas, 1986).    Blocking GROα or the 
CXCR2 receptor impair melanoma cell proliferation in vitro (Owen et al., 1997). In 
vivo studies demonstrated that overexpression of GROα, GROβ or GROγ in 
different tumor-derived cell lines enhances their colony-forming activity and 
tumorigenicity in nude mice (Owen et al., 1997). 
Strong correlation between chronic inflammation and carcinogenesis most  
notably arising in patients with bowel inflammatory diseases, for example, chronic 
ulcerative colitis and Crohn’s disease. Liver carcinoma is precursor of chronic 
hepatitis C infection. Schitosomiasis predisposes to bladder and colon cancer. An 
increase risk of stomach cancer is associated with chronic Helicobacter pylori 
infection (Ernst & Gold, 2000). 
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1.4 Inflammation & Angiogenesis 
Inflammation is biological response of vascular tissues to injury, irritants or 
pathogens (Mariathasan et al., 2006). The inflammatory process induced in the 
afflicted tissue to facilitate the access of immune cells to the affected tissue in 
attempt to heal the affliction. The reaction is associated with multifactor network of 
chemical signals which include the release of pro-inflammatory cytokines namely 
TNF-α and IL-1α. Signaling pathways studies revealed strong association between 
angiogenesis and inflammation (Y. Kim et al., 2011).  For example the activated 
macrophages during development of melanoma produce TNF-α, IL-1, arachidonate 
metabolites and extracellular proteases, melanocytes express IL-18 and VEGF-A, 
thereby induce angiogenesis (Torisu et al., 2000). Immune cells posses on the 
surface toll like receptors (TLRs), when it stimulated by bacteria antigen, it release 
pro-inflammatory cytokines from the activated dendritic cells that recruit the 
endothelial cells of the blood vessels to synthesize pro-inflammatory mediators such 
as prostaglandins and pro-inflammatory cytokines like IL-1 and TNF-α via up-
regulation of gene transcription factors such as NF-kB. Neoplastic cells mimic same 
mechanisms to trigger angiogenesis from the endothelial cells (Y. Kim et al., 2011).  
Angiogenesis is highly regulated and strictly controlled. It is crucial for 
tissue development, growth and repair, although was found associated with chronic 
inflammatory diseases, such as rheumatoid arthritis, fibrosis and psoriasis, as well as 
with tumor growth and metastasis (Douglas Hanahan & Weinberg, 2000).    
Cell adhesion molecules (CAM) are transmembrane receptors which facilitate 
adhesion to neighboring cells or the extracelluar matrix leading to multiple cellular 
processes such as cell migration, proliferation, morphogenesis, cell survival and 
gene expression. The over-expression of cell adhesion molecules plays a 
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fundamental role in recruitment of inflammatory cells from blood circulation to the 
inflamed tissue. Study in rat cornea revealed that endothelial adhesion molecules (E-
seletin) and vascular cell adhesion molecule-1(VCAM-1) promote angiogenesis 
(Kräling et al., 1996).  Blocking these CAMs by cyclic peptide or monoclonal 
antibodies not only inhibited inflammation, but also disrupt ongoing angiogenesis on 
chick chorioallantoic membrane (CAM) as well as ocular angiogenesis (Brooks et 
al., 1994). D-penicillamine is immunosupressor drug used to treat rheumatoid 
arthritis, showed profound antiangiogenic effect by inhibition endothelial cell 
migration, it believed that it suppress rheumatoid synovitis by quiescent the blood 
vessels from neovascularization for the emigration of chronic inflammatory cells 
(Matsubara & Ziff, 1987). Current drugs of rheumatoid arthritis such as 
methotrexate and gold compounds are proved to have anti-angiogenic effects 
(Colville-Nash & Seed, 1993). Non-steroidal anti-inflammatory drugs (NSAIDs) 
such as aspirin, indomethacin and ibuprofen are reported to inhibit inflammatory 
angiogenesis that is partly induced by PGE2, through direct effects on endothelial 
cells and modulation of COX-1 and COX-2 (Jones et al., 1999). Angiogenesis 
crucial for wound and ulcer healing, to supply oxygen and nutrients to the healing 
site, NSAIDs inhibited angiogenesis in gastric ulcer healing (Tarnawski et al., 
1989). It evident from previous studies there is strong relation between inflammation 
and angiogenesis and antiiflammatory drugs have antiangiogenic efficacy and vice 
versa.  
1.5 Antiangiogenic therapy  
Antiangiogenic therapy is antitumor strategies that target the formation of 
know blood vessels that supply oxygen and nutrient to actively proliferating cancer 
cells, thus suppressing tumor growth and metastasis. Almost all anticancer agents 
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used in clinical settings for chemotherapy targeting rapidly dividing neoplastic cells, 
have serious adverse effects such as immunosuppression, intestinal disorder and hair 
loss (Kubota, 2012). On the other hand antiangiogenic therapy have very less side 
effects because vasculature is stable in adults under normal physiological condition 
except in the uterine endometrium during the menstrual cycle, beside antiangiogenic 
normally not cytotoxic, moreover some of them are antioxidant, which improve 
patient health. 
 
1.5.1 Mechanisms of Anti-angiogenesis Therapy 
  Judah Folkman 1971 emphasized the strong relation of tumor vasculature 
and tumor growth, and if the tumor couldn’t to establish its own blood vessels, it 
would wither and die, ever since there is growing number of antiangiogenic agents 
out of many studies. Antiangiogenic agents work by interfering with the key steps of 
angiogenesis. Vascular endothelial growth factor (VEGF) plays a central role in 
tumor angiogenesis (N. Ferrara, 2009). The expanding tumor tissue rapidly consume 
oxygen and tumor tissue specially the core of the tumor become hypoxic, which lead 
to activation of hypoxia-inducible factor (HIF) signaling in hypoxic-sensing cells 
stimulates VEGF expression, in turn it triggers microvessels growth (P. Carmeliet et 
al., 1998; Semenza et al., 1999). Anti-VEGF therapy is the most established 
antiangiogenic modalities. Several preclinical antitumor studies by administration of 
VEGF inhibitors have shown profound tumor suppression activity in different type 
of malignancies (N. Ferrara & Kerbel, 2005; K Jin Kim et al., 1993). Clinical studies 
on patient with metastasic colorectal cancer, administration of anti-VEGF 
monoclonal antibody (bevacizumab) showed significant efficacy in combination 
with 5-fluorouracil, subsequently U.S. Food and Drug Administration (FDA) 
approved bevacizumab in combination with 5-FU-based regimens for the treatment 
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of metastatic colorectal cancer (Peter Carmeliet & Jain, 2011; Venook, 2005). Some 
drugs induce apoptosis or inhibit the growth and migration of endothelial cells 
leading to shutdown of blood flow to the tumors, such as endostatin and 
Combretastatin A-4 (Tozer et al., 1999). Some drugs neutralize angiogenic 
molecules such as FGF and VEGF, where as some agents neutralize angiogenic 
factors that interfere with vascular basement membrane and extracellular matrix, 
hence affect cell invasion and migration such as MMPs inhibitor (Suramin) and 
some antibodies that interrupt adhesion molecules (anti-intergin alpha v beta 3).  
 
1.5.2 Tyrosine kinase inhibitors 
Tyrosine kinases are enzymes that catalyze the transfer of γ phosphate group 
from ATP to target proteins.  They regulate different cellular processes and 
associated with the cytoplasmic domains of growth factor receptors as well as 
oncoproteins and many have the potential to cause transformation if mutated or 
hyperexpressed (Pawson, 2002; Workman, Brunton, & Robins, 1992). Therefore, 
Tyrosine kinases are an excellent target for cancer therapy, because they can 
modulate cancer-specific molecules and signaling pathways and may have limited 
nonspecific toxicities. Tyrosine kinase inhibitors (TKIs) are pharmaceutical small 
molecules orally active and well-tolerated. They have been found to have promising 
cytostatic and antitumor activity and now some of them approved for treatment of 
several malignancies such as breast, lung, kidney and pancreatic cancer as well as 
gastro-intestinal stromal tumors and chronic myeloid leukemia (Shawver, Slamon, 
& Ullrich, 2002). Examples of some tryrosine kinase inhibitors that inter clinical 
arena: 
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1.5.2.1 BCR-ABL Tyrosine Kinase Inhibitors  
Translocation or abnormality (Philadelphia chromosome) is associated with 
95% of patient with chronic myeloid leukemia (Epstein et al., 1999). The formation 
of the BCR-ABL oncogenes due to fusion of the BCR gene on chromosome 22 and 
the ABL tyrosine kinase gene on chromosome 9 leading to expression of protein-
tyrosine kinases (BCR-ABL). The subsequent dysregulation of intracellular 
signaling enhances proliferation of myeloid cells and induce resistance to apoptosis 
of hematopoietic stem or progenitor cells (Druker et al., 2001). Imagtinib was found 
to inhibit or kill proliferating myeloid cell containing BCR-ABL protein which is 
unique to leukemic cells and expressed at high levels in patients (Drevs et al., 2000). 
 
1.5.2.2 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors 
The epidermal growth factor receptor found implicated in most common 
human epithelial cancers and it has been associated with cancer cell proliferation, 
invasion, angiogenesis, metastasis and resistance to chemotherapy. Blocking 
(EGFR) emerged as promising therapeutic strategy against tumorigenesis. Studies 
revealed that (EGFR) can be inhibited by monoclonal antibodies or tyrosine kinase 
inhibitors (TKIs) (Ciardiello, 2000; Ranson, 2004). Several small molecules that 
block the ligand-induce activation of (EGFR) have been developed such as 
quinazolines, gefitinib and erlotinib, which are the most advanced in clinical 
development, are competitive inhibitors at the tyrosine kinase ATP binding site, also 
Irreversible inhibitors that bind to specific cysteines in the ATP-binding pocket of 
EGFR family receptors have been developed such as CI-1033 and EKB-569, in 
addition to exploring agents with homologous structures of EGFR receptor (Arora & 
Scholar, 2005; Janmaat & Giaccone, 2003). 
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1.5.2.3 Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors 
  Vascular endothelial growth factor (VEGF) is probably the most important 
growth factor that is involved in tumor angiogenesis, and it has a important role in 
the growth and progression of solid tumors (Hicklin & Ellis, 2005). Binding of the 
ligand VEGF-A to VEGFR-1 induces endothelial cell migration. VEGFR-2 believed 
to induce endothelial cell proliferation, permeability, and survival. Binding of VEGF 
to VEGFR-2 receptors leads to activation and autophosphorylation of intracellular 
tyrosine kinase domains, with initiation of intracellular signaling cascade 
(Bergsland, 2004; Parikh & Ellis, 2004). Tyrosine kinase inhibitors inter clinical 
arena are low molecular-weight that mimics ATP proteins and able to bind to the 
ATP-binding catalytic site of tyrosine kinase domain of VEGFRs, consequently 
block the intracellular signaling.  
These (TKIs) agents include  
 Semaxinib (SU5416) is small lipophilic molecule, with high protein-bound 
affinity and non-selective receptor tyrosine kinase inhibitor of VEGFs 
(Mendel et al., 2000). It showed profound antiangiogenic and antitumor 
efficacy in preclinical studies and it was the first VEGFR tyrosine kinase 
inhibitor to be investigated in clinical settings (Stopeck et al., 2002).  
 Vatalanib (PTK787/ZK222584) which is a synthetic, orally bio-available 
agent, selective inhibitor of VEGFR-1 and VEGFR-2, although it most 
potent against VEGFR-2, also in higher concentrations it inhibits other 
tyrosine kinases such as PDGFR-β, c-MET and c-FMS (Lin et al., 2002). 
Preclinical studies have shown that vatalanib inhibited growth of implanted 
human tumor xenografts in nude mice and reduced microvasculature (Wood 
et al., 2000). Vatalanib entered the clinical arena as a single drug as well as 
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in combination with chemotherapy for treating colon cancer, advanced 
prostate and renal cell cancer, and relapsed/refractory glioblastoma 
multiforme, where VEGF overexpression has been demonstrated (Arora & 
Scholar, 2005; Bergsland, 2004).  
 Sutent (SU11248): is multitargeted receptor tyrosine kinase inhibitor of 
VEGFR, PDGFR, c-KIT, and FLT-3 kinase activity as well as PDGFR-β, 
and c-Kit, with antiproliferative and antiangiogenic activity (O'Farrell et al., 
2003). Phase III clinical trials with kidney cancer using sutent as a single 
agent and in combination chemotherapy are ongoing. It has demonstrated 
both efficacy and safety in these trials. It is also being studied in a phase III 
trial for imatinib-resistant GISTs. Sutent delayed the time of tumor 
progression on average from 1.5 to 6.3 months and also significantly reduced 
the death rate (Demetri et al., 2005). 
 Sorafenib (BAY 43-9006): is a novel bi-aryl urea, it has double functions, its 
Raf kinase and VEGFRs inhibitor. Initially it was developed as Raf kinase 
inhibitor, subsequent studies shown that it can inhibit variety of kinase 
receptors, including VEGFR, EGFR, and PDGFR kinases (Strumberg et al., 
2005; S. M. Wilhelm et al., 2004). Thus, Sorafenib inhibits cell proliferation 
as well as angiogenesis. Studies reveals that it has pronounce efficacy on: 
colon, pancreatic, lung, renal and ovarian neoplasm (S. M. Wilhelm et al., 
2004).  Intracellular activation of PDGFR receptors (α and β) results in cell 
transformation and generation of mitotic signal. These two receptor types are 
overexpressed in several solid tumors as well as in surrounding storma 
(Sedlacek, 2000).  
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1.5.2.4 Platelet-Derived Growth Factor Inhibitors  
Signal transduction of Platelet-derived growth factor (PDGF) is through cell 
surface tyrosine kinase receptor (PDGFR) to stimulate various cellular functions, 
including growth, proliferation, and differentiation (Sedlacek, 2000). Leflunomide is 
small organic molecule that inhibits PDGF-mediated signaling events, including 
receptor tyrosine phosphorylation, DNA synthesis, cell cycle progression, and cell 
proliferation. basically immunosuppressive disease-modifying anti-rheumatic drug, 
it reduces signs and symptoms of the disease and attenuate structural damage 
(Dougados et al., 2005). Leflunomide proved to have antitumor in several preclinical 
studies. It effectively inhibited the growth of tumor xenografts that expressed 
PDGFR more than xenografts not expressing this receptor. A multi-institutional 
phase II study in hormone refractory prostate cancer patients with leflunomide 
revealed partial responses in 1 of 19 patients, a prostate- specific antigen decreased 
by more than 50% in 3 of 39 patients, as well as reduction in pain. The most 
frequently reported side effects with leflunomide were asthenia, nausea, anorexia, 
and anemia (Ko et al., 2001).  
1.6 Programmed cell death (PCD) 
Programmed cell death or apoptosis morphologically characterized by 
refraction of cell component, followed by DNA condensation and cytoplasmic 
shrinkage. Subsequently cell membrane shows blebs or spikes that are separate from 
the dying cell to form “apoptotic body”. The phospholipid asymmetry in the cell 
membrane of apoptotic cells no longer intact, moreover some changes appear in the 
mitochondrial outer membrane such as loss of its electrochemical gradient by 
formation of pores and leakage of cytochrome C into cytoplasm beside the 
appearance of phosphotidyl serine (PS) on the outer leaflet of the cell membrane. In 
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final step, the surrounding cell or macrophages phagocytose apoptotic bodies and 
the dying cell. Apoptosis is highly regulated process, arguably, involved the 
genetically programmed i.e., programmed cell death. In other words apoptosis is 
mediated by an intracellular program, which generally confers advantage during an 
organism's life-cycle (Formigli et al., 2000; Yi Lu, 2009).The events of apoptosis 
stand in contrast to necrosis, which describes uncontrolled process cell death due to 
exposure to harmful material or acute injury. The cytoplasm and mitochondria of the 
necrotic cell swell, and subsequently the cell bursts and many of its internal 
organelles spill over surrounding tissue, which more likely inflammatory responses 
are provoked (Raff, 1998). While there is no inflammatory reaction associated with 
apoptosis because there is no release of cellular content of apoptotic cell into the 
surrounding interstitial tissue, beside the apoptotic cell phagocytosed by adjacent 
cells thus likely preventing secondary necrosis, in addition the engulfing cells do not 
produce anti-inflammatory cytokines (Ortiz-Arduan & Neilson, 1994). 
 
Table 1.1: depicts comparison between some of the major features of apoptosis and necrosis 
(Gold et al., 1994). 
Feature   Apoptosis         Necrosis   
Cell volume    Decreased        Increased   
Plasma membrane integrity    Preserved       Lost 
Plasma membrane structure    Characteristic blebbing         Lost   
Cell-cell adhesion    Lost early        Typically preserved   
Cell matrix adhesion    Lost early           Lost late   
Exfoliation of cells    Early, as single cells       Late, as sheets of cells 
Chromatin     Condensed          Preserved   
Nuclear fragmentation    Characteristic         Absent 
Cytosolic contents    Preserved          Released   
Apoptotic bodies    Characteristic         Absent   
Phagocytosis    Characteristic         Absent   
Inflammatory response    Absent        Characteristic   
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 Apoptosis and mitosis both play an important role in normal physiology 
fulfilling opposite but complementary needs to maintain homeostasis in the adult 
body. Therefore  change in apoptosis rate (too little or too much cell death) may lead 
to pathology, hyper-activation of apoptosis could be a sign of some ailment such as 
neurodegenerative diseases (such as Parkinson’s disease, Alzheimer’s disease, 
Huntington’s disease), ischemia-associated injury, Amyotrophic Lateral Sclerosis, 
and autoimmune disease like autoimmune syndrome (AIDS) as precursor of an 
infection with human immunodeficiency (HIV). In contrast apoptosis process is 
important in development of immune and nervous system when there is 
overproduction of cells, which cause  death to the cells that no longer have 
reproductive antigen specificities or functional synaptic links (Nijhawan, Honarpour, 
& Wang, 2000; Opferman & Korsmeyer, 2003). Moreover, Apoptosis play 
fundamental role to eradicate pathogen-infected cells, in addition to its important 
role in wound healing in wiping the inflammatory cells and formation of granulation 
tissue into scar tissue (Elmore, 2007).  
 In cancer, apoptosis play a important role in suppressing carcinogenesis 
because the mechanisms of cell cycle are up-regulated either with an over 
proliferation of cells and/or decreased removal of cells (King & Cidlowski, 1998). 
Therefore suppression of apoptosis during carcinogenesis is thought to count for the 
development and progression of some cancers (Kerr, Winterford, & Harmon, 1994). 
 
1.6.1 Apoptosis mechanisms  
The mechanisms of apoptosis are very complex and sophisticated, involving 
an energy-dependent cascade of molecular events. Apoptotic signaling events 
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involve two main pathways: mitochondrial pathway (intrinsic) and death receptor 
pathway (extrinsic) (figure1.1)  
 
1.6.1a Intrinsic Pathway 
The intrinsic signaling pathways involve different non-receptor-mediated 
stimuli that produce intracellular signals that targets mitochondrial-initiated events 
within the cell. The stimuli that trigger the intrinsic pathway produce intracellular 
signals that may act in either direct or indirect fashion, the directly by radiation, 
toxins, hypoxia, hyperthermia, viral infections, and free radicals. The indirect 
fashion via the absence of specific growth factors and cytokines which are 
responsible of suppressing of cell death (like anti-apoptotic Bcl-2 family members 
including Bcl-2 and Bcl-XL), therefore masking these anti-apoptotic protein results 
in initiation apoptosis(Elmore, 2007). As a result of all these stimuli some changes 
occur in the inner mitochondrial membrane leading to mitochondrial permeability 
transition (MPT) pore, loss of mitochondrial integrity and release of cytochrome c , 
Smac/DIABLO and serine protease HtrA2/Omi(Du, Fang, Li, Li, & Wang; Garrido 
et al., 2006; van Loo et al., 2002). Cytochrome c activates procaspases-9, 
accumulation of procaspase-9 leads to activation of caspases-9.Smac/DIABLO and 
HtrA2/Omi are believed to promote apoptosis by inhibiting IAP (inhibitors of 
apoptosis proteins) activity. After triggering the apoptosis process, another group of 
pro-apoptotic proteins (AIF, endonuclease G and CAD will be released. 
The second group of pro-apoptotic proteins, AIF, endonuclease G and CAD, are 
released from mitochondria. AIF cause DNA fragmentation and condensation of 
peripheral nuclear peripheral nuclear chromatin (Joza et al., 2001). 
 
